Almost there!
Confronting the Threat to US Biomedical Innovation
Finally, in Chapter 8, we explored Future Solutions. We discussed price controls (and their risks), international reference pricing, and smarter models like GCEA.
Key Takeaway: To save the Biotech Social Contract, we must lower patient costs (OOPs) while maintaining the incentives that drive the discovery of new cures.